Cilofexor

( DrugBank: Cilofexor / KEGG DRUG: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
93	原発性胆汁性胆管炎	1

告示番号	疾患名（ページ内リンク）	臨床試験数
94	原発性硬化性胆管炎	12

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02943447 (ClinicalTrials.gov)	December 1, 2016	13/6/2016	Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexorin Adults With Primary Biliary ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Biliary Cholangitis	Drug: Cilofexor;Drug: Placebo to match cilofexor	Gilead Sciences	NULL	Terminated	18 Years	70 Years	All	71	Phase 2	United States;Austria;Canada;United Kingdom

First Previous1Next Last

94. 原発性硬化性胆管炎

臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

trials per page:

Showing 1 to 10 of 12 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-000204-14-AT (EUCTR)	13/12/2019	26/06/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS ...	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	421	Phase 3	United States;Finland;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Canada;Belgium;De ...
2	EUCTR2019-000204-14-DK (EUCTR)	08/11/2019	08/07/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS ...	Gilead Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	421	Phase 3	Netherlands;Germany;Japan;New Zealand;Sweden;United States;Finland;Spain;Austria;Israel;Switzerland; ...
3	EUCTR2019-000204-14-BE (EUCTR)	04/11/2019	25/06/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS ...	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	421	Phase 3	United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Au ...
4	NCT04060147 (ClinicalTrials.gov)	October 17, 2019	15/8/2019	Safety and Tolerability of Cilofexorin Participants With Primary Sclerosing Cholangitis (PSC) and Co ...	A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexorin Subjects ...	Primary Sclerosing Cholangitis;Compensated Cirrhosis	Drug: CILO	Gilead Sciences	NULL	Completed	18 Years	N/A	All	11	Phase 1	United States
5	EUCTR2019-000204-14-FR (EUCTR)	26/09/2019	02/08/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Code: GS-9674 INN or Proposed INN: cilofexor Other descriptive name: GS-9674 Product Code: GS-9 ...	Gilead Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 3	United States;Finland;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Au ...
6	EUCTR2019-000204-14-FI (EUCTR)	11/09/2019	24/06/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS ...	Gilead Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	421	Phase 3	United States;Finland;Spain;Austria;Israel;Switzerland;United Kingdom;Italy;France;Canada;Belgium;Au ...
7	EUCTR2019-000204-14-ES (EUCTR)	29/08/2019	12/09/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 Product Code: GS-9 ...	Gilead Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 3	United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Au ...
8	EUCTR2019-000204-14-GB (EUCTR)	15/07/2019	27/06/2019	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS ...	Gilead Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 3	United States;Finland;Spain;Austria;Israel;Switzerland;United Kingdom;Italy;France;Canada;Belgium;Au ...
9	EUCTR2019-000204-14-IT (EUCTR)	12/07/2019	29/01/2021	A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Scl ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Pr ...	Product Name: Cilofexor Product Code: [GS-9674] INN or Proposed INN: Cilofexor Product Name: Cilofexor P ...	GILEAD SCIENCES INCORPORATED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 3	United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Au ...
10	NCT03890120 (ClinicalTrials.gov)	March 27, 2019	25/3/2019	Safety, Tolerability, and Efficacy of Cilofexorin Non-Cirrhotic Adults With Primary Sclerosing Chola ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, a ...	Primary Sclerosing Cholangitis	Drug: Cilofexor;Drug: Placebo	Gilead Sciences	NULL	Terminated	18 Years	75 Years	All	419	Phase 3	United States;Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New ...

First Previous1 2Next Last